NL-OMON26488
Completed
Not Applicable
Prediciton of medication response in children with ADHD: EEG differences between responders and non-responders to methylphenidate.
trecht Institute for Pharmaceutical Sciences, Utrecht University0 sites50 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- ADHD, methylphenidate response, EEG, DNA, CANTAB, spatial span, spatial working memory, stop-task, CPT, theta/beta ratio
- Sponsor
- trecht Institute for Pharmaceutical Sciences, Utrecht University
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosed with ADHD combined type (no primary diagnoses of attention deficit) according to DSM IV criteria (DSM IV, APA
Exclusion Criteria
- •1\. IQ is below 75;
- •2\. One or more of the following comorbid disorders are diagnosed: anxiety disorder,
- •depression, tics, psychosis or autism;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prediction of medication response in children with Attention Deficit Hyperactivity Disorder (ADHD): Electroencephalogram (EEG) differences between responders and non-responders to methylphenidateMedication response in children with Attention Deficit Hyperactivity Disorder (ADHD)Mental and Behavioural DisordersHyperkinetic disordersISRCTN32841168trecht Institute for Pharmaceutical Sciences (The Netherlands)50
Recruiting
Not Applicable
Early prediction of treatment response in children with Inflammatory Bowel Disease with Intestinal UltrasoundNL-OMON51551Academisch Medisch Centrum120
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateEUCTR2011-001785-17-PLOctapharma AG50
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-001785-17-CZOctapharma AG60
Active, not recruiting
Phase 1
Follow-Up study in Previously Treated Children to investigate a new FVIII concentrateSevere Haemophilia AMedDRA version: 14.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2011-001785-17-FROctapharma AG60